摘要
目的探讨亚砷酸治疗难治性恶性淋巴瘤的临床疗效及安全性。方法 2009年5月～2010年4月期间本院收治的难治性恶性淋巴瘤患者12例,三氧化二砷10 mg/d,加入50 g/L葡萄糖注射液500 mL中,静脉滴注,1次/d,d1～d20。之后选用DHAP或ABVD方案进行化疗。治疗后观察疗效及不良反应发生情况。结果 12例患者中,获CR 1例,PR 7例,SD 2例,PD 2例,有效率为66.7%(8/12)。不良反应主要有骨髓抑制、肝肾功能损伤、腹胀等,经对症治疗均缓解。结论亚砷酸联合化疗治疗难治性恶性淋巴瘤临床效果满意,值得临床推广。
Objective To explore the clinical efficacy and safety of Arsenic trioxide in the treatment of refractory malignant lymphoma.Methods Twelve patients with refractory malignant lymphoma who were admitted to hospital during May 2009 and April 2010 were given arsenic trioxide 10 mg/d,adding 50 g/L glucose injection 500 mL with intravenous infusion,1 time/d,d1～d20.Then DHAP or ABVD chemotherapy program were carried out.After treatment,the efficacy and side effects were observed.Results The results were as follows： CR 1 case,PR 7 cases,SD 2 cases,PD 2 cases.The effective rate was 66.7%（8/12）.The main side effects were bone marrow suppression,liver and kidney dysfunction and abdominal distension.After symptomatic treatment,all these side effects were eased.Conclusion Arsenic trioxide combined with chemotherapy in the treatment of refractory malignant lymphoma has satisfactory clinical results and is worthy of promotion.
出处
《实用临床医药杂志》
CAS
2011年第15期86-88,共3页
Journal of Clinical Medicine in Practice
关键词
三氧化二砷
恶性淋巴瘤
化疗
Arsenic trioxide
malignant lymphoma
chemotherapy
